FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W69014308> ?p ?o ?g. }

• W69014308 endingPage "93" @default.
• W69014308 startingPage "85" @default.
• W69014308 abstract "Estrogen replacement therapy, in spite of efficacy in the prevention of osteoporotic fractures, has significant side effects and risks that limit its widespread usage in postmenopausal women. Thus significant medical need exists to find modalities that prevent osteoporosis, but without the side effects of estrogen. Selective estrogen receptor modulators (SERMs) have the potential to provide the skeletal benefits of estrogen without the increased risk of uterine and breast cancer. Tamoxifen, a first generation SERM is approved for the prevention and treatment of breast cancer, and raloxifene, a second generation SERM has been approved for the prevention and treatment of osteoporosis. Lasofoxifene, a new potent, nonsteroidal SERM, binds with high affinity to human estrogen receptors and acts as a tissue selective estrogen antagonist or agonist. In preclinical models of postmenopausal osteoporosis, lasofoxifene inhibited bone turnover and prevented bone loss throughout the skeleton. In studies designed to investigate the combination of lasofoxifene with estrogen, lasofoxifene blocked the hypertrophic effects of estrogen in the uterus, but did not block the bone protective effects. In immature and aged female rats, lasofoxifene did not affect the uterine weight and uterine histology. In preclinical studies designed to evaluate the effects of lasofoxifene on the uterus, a slight increase in wet uterine weight was observed in immature and aged female rats, but this difference was not observed in dry uterine weight suggesting that the increased uterine weight was due to increased water content in the tissue. In preclinical studies designed to evaluate the effects of lasofoxifene in breast cancer, lasofoxifene inhibited breast tumor formation in mice injected with human MCF-7 breast cancer cells and in rats bearing mammary carcinomas. Thus, in preclinical models, lasofoxifene, a next generation SERM, prevents estrogen deficiency-induced bone loss, inhibits breast tumor formation, and reduces serum cholesterol, without causing uterine hypertrophy. These data suggest that lasofoxifene is a new potential therapy for the prevention of osteoporosis in postmenopausal women." @default.
• W69014308 created "2016-06-24" @default.
• W69014308 creator A5040206270 @default.
• W69014308 creator A5050621294 @default.
• W69014308 creator A5073780815 @default.
• W69014308 creator A5073985390 @default.
• W69014308 date "2004-10-01" @default.
• W69014308 modified "2023-09-23" @default.
• W69014308 title "[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]." @default.
• W69014308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15577137" @default.
• W69014308 hasPublicationYear "2004" @default.
• W69014308 type Work @default.
• W69014308 sameAs 69014308 @default.
• W69014308 citedByCount "2" @default.
• W69014308 countsByYear W690143082013 @default.
• W69014308 crossrefType "journal-article" @default.
• W69014308 hasAuthorship W69014308A5040206270 @default.
• W69014308 hasAuthorship W69014308A5050621294 @default.
• W69014308 hasAuthorship W69014308A5073780815 @default.
• W69014308 hasAuthorship W69014308A5073985390 @default.
• W69014308 hasConcept C121608353 @default.
• W69014308 hasConcept C126322002 @default.
• W69014308 hasConcept C134018914 @default.
• W69014308 hasConcept C2776541429 @default.
• W69014308 hasConcept C2777164284 @default.
• W69014308 hasConcept C2777176818 @default.
• W69014308 hasConcept C2777944059 @default.
• W69014308 hasConcept C2779889926 @default.
• W69014308 hasConcept C530470458 @default.
• W69014308 hasConcept C71924100 @default.
• W69014308 hasConcept C84606932 @default.
• W69014308 hasConcept C98274493 @default.
• W69014308 hasConceptScore W69014308C121608353 @default.
• W69014308 hasConceptScore W69014308C126322002 @default.
• W69014308 hasConceptScore W69014308C134018914 @default.
• W69014308 hasConceptScore W69014308C2776541429 @default.
• W69014308 hasConceptScore W69014308C2777164284 @default.
• W69014308 hasConceptScore W69014308C2777176818 @default.
• W69014308 hasConceptScore W69014308C2777944059 @default.
• W69014308 hasConceptScore W69014308C2779889926 @default.
• W69014308 hasConceptScore W69014308C530470458 @default.
• W69014308 hasConceptScore W69014308C71924100 @default.
• W69014308 hasConceptScore W69014308C84606932 @default.
• W69014308 hasConceptScore W69014308C98274493 @default.
• W69014308 hasIssue "10" @default.
• W69014308 hasLocation W690143081 @default.
• W69014308 hasOpenAccess W69014308 @default.
• W69014308 hasPrimaryLocation W690143081 @default.
• W69014308 hasRelatedWork W1514515741 @default.
• W69014308 hasRelatedWork W1579574229 @default.
• W69014308 hasRelatedWork W1986507544 @default.
• W69014308 hasRelatedWork W2006360026 @default.
• W69014308 hasRelatedWork W2061974211 @default.
• W69014308 hasRelatedWork W2072183288 @default.
• W69014308 hasRelatedWork W2080291907 @default.
• W69014308 hasRelatedWork W2116581459 @default.
• W69014308 hasRelatedWork W2149124957 @default.
• W69014308 hasRelatedWork W2460088065 @default.
• W69014308 hasVolume "14" @default.
• W69014308 isParatext "false" @default.
• W69014308 isRetracted "false" @default.
• W69014308 magId "69014308" @default.
• W69014308 workType "article" @default.